Previous single-center KEY-NOTE-001 study showed superior clinical benefits with pembrolizumab in EGFR-mutant patients with no prior tyrosine kinase inhibitor (TKI) treatment versus those received a TKI. This phase II study evaluated patients with EGFR mutation positive and PD-L1 positive (>1%), advanced NSCLC. Lack of efficacy after treating 11 of 25 planned patients led to termination of study enrollment. The treatment naïve group accounted for 82% of trial patients, 64% had sensitizing EGFR mutations, and 73% had PD-L1 expression >50%. The objective response found in one patient (ORR ¼ 9%) was later confirmed to be independent of EGFR mutation. No new drug-related adverse events with pembrolizumab, while 2 deaths within 6 months of enrollment were of concern. Taken together, the authors concluded that pembrolizumab is not appropriate for the treatment of patients with advanced NSCLC, who are TKI naive, EGFR-mutation positive, and PD-L1 positive. The retrospective study analyzed 39 multiinstitutional patients with BRAF-mutant NSCLC. The group harboring BRAF V600E (Group A) had high (50%), intermediate (1-49%) , and no (<1%) PD-L1 expression in 42%, 32%, and 26% of patients while the group with BRAF non-V600E (Group B) had 50%, 10%, and 40%, respectively. High tumor mutational burden (TMB) was found in 25% of Group A, of which no high microsatellite instability status (MSI) was observed. Among the 22 patients receiving immune check-point inhibitors (ICPi), objective response rate (ORR) was 25% in Group A and 33% in Group B. Median progression-free survival (PFS) with ICPi was 3.7 months and 4.1 months, respectively (p¼0.37). Response probability and PFS were independent of BRAF This report presented the mature overall survival (OS) data for the intention-to-treat population of ARCHER 1050, comparing dacomitinib (n¼227) with gefitinib (n¼225) in patients with advanced NSCLC harboring EGFR-activating mutations. Dacomitinib and gefitnib arms had 45.4% and 52.0% deaths, respectively at a median follow-up of 31.3 months. The dacomitinib arm achieved a median OS of 34.1 months versus 26.8 months in the gefitinib arm (estimated hazard ratio ¼ 0.760; P ¼ 0.044), with 30-month OS rates of 56.2% versus 46.3%. The authors concluded that dacomitinib is the first second-generation epidermal growth factor receptor tyrosine kinase inhibitor (TKI) that confers significant OS improvement versus standard-of-care TKI in this setting, supporting its use as a standard therapy for these patients. The next-generation ALK inhibitor, Brigatinib was evaluated in patients with ALK-NSCLC with brain metastases in a phase I/II trial and in a subsequent randomized phase II trial ALTA. Baseline brain metastases were found in most patients analyzed (63% in phI/II, 71% and 66% in ALTA arms A [90 mg once daily] and B [180 mg daily with 7-day lead-in at 90 mg], respectively), with 46%, 40% and 41%, respectively, without prior brain radiotherapy. Crizotinib was given to all patients except four in phI/II. Confirmed intracranial objective response rate (ORR) was 53% in phI/II, 46% and 67% in ALTA arms A and B, respectively. Similar intracranial ORRs were found in subgroups without prior radiation or progression postradiation. Median intracranial progression-free survival (iPFS) was 14.6 months in phI/II, 15.6 months in arm A and 18.4 months in arm B of ALTA. The data suggest substantial intracranial responses and durable iPFS with brigatinib in this patient population, who had the highest iPFS when given 180 mg/day with lead-in. 
Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening
The prospective study compared the US screening populations from the National Health Interview Survey M2012 , LCRAT, and LCDRAT) were well-calibrated (expectedobserved ratio range, 0.92 to 1.12), with higher areas under the curve (AUCs; range, 0.75 to 0.79). These models also showed the highest sensitivity at a fixed specificity (and vice versa) and similar discrimination at a fixed risk threshold. Better agreement was achieved on these models on screening population size, with consensus on 73% of persons chosen. All in all, these 4 models accurately predicted risk and achieved best performance in selecting eversmokers for screening, warranting further optimization to improve performance in certain subpopulations. 
Nicotine Replacement Therapy versus Control for Smoking Cessation
The study evaluated the effectiveness and safety of nicotine replacement therapy (NRT) in long-term smoking cessation versus placebo or no NRT. Randomized trials (n¼133) from the Cochrane Tobacco Addiction Group with 64,640 participants were assessed. The risk ratio (RR) of abstinence for any form of NRT versus control was 1.55, with pooled RR of 1.49 for nicotine gum, 1.64 for nicotine patch, 1.52 for oral tablets/lozenges, 1.90 for nicotine inhalator, and 2.02 for nicotine nasal spray. The effects were mostly independent of the definition of abstinence, the intensity of additional support provided or the setting NRT was offered. Significant benefit of NRT on abstinence was observed in pregnant women close to the time of delivery (RR 1.32; 2129 participants), but not post-partum (RR 1.29; 1675 participants). The odds ratio (OR) of chest pains or palpitations for any form of NRT relative to control was 1.88. To conclude, all licensed NRT forms help increase success in smoking cessation by 50% to 60%, regardless of setting. More intense levels of support are not essential to the success of NRT. NRT is associated with minor irritation at the site of administration, and rare cases of non-ischaemic chest pain and palpitations. 
Of the 128 studies selected, highest implementation was observed in smoke-free laws, health warnings and education campaigns, youth access laws, and reporting/information exchange whereas it was lowest in measures to counter industry interference, regulate tobacco product contents, promote alternative livelihoods and protect health/environment. Price/tax increases, comprehensive smoking and marketing bans, health warnings, and cessation treatment are associated with decreased tobacco consumption/health risks and increased quitting. Mass media campaigns and youth access laws prevent smoking initiation, decrease prevalence and promote cessation. To conclude, implementation of measures has increased across several policy domains, leaving impacts on tobacco consumption, prevalence and other outcomes. FCTC implementation must be accelerated, and all Parties' Treaty obligations should be met, and strategies exceeding minimum requirements should be considered. The first assessment of lung cancer screening rates in 2016 across 1,800 lung cancer screening sites nationwide since US Preventive Services Task Force (USPSTF) and ASCO screening recommendations demonstrated that only 1.9% of 7,612,965 eligible current and former heavy smokers received low-dose CT screening. The most accredited screening sites were found in the South (n¼663), with the highest number of smokers eligible for screening (3,072,095) while the West had the lowest number of accredited screening sites (n¼232). The highest screening rate was in the Northeast (3.5%), followed by the Midwest (1.9%), and the South (1.6%) while the West had the lowest rate (1.0%). The reasons of inadequate screening are unclear. Further strategies are needed to raise awareness and mandate lung cancer screening. KEYNOTE-042 is the largest study of pembrolizumab as a monotherapy versus chemotherapy (paclitaxel plus carboplatin or pemetrexed plus carboplatin) in the first-line setting for patients with advanced non-small cell lung cancer (NSCLC). The analysis of 1,274 patients showed that those treated with pembrolizumab had a longer median overall survival versus those receiving chemotherapy, regardless of tumor PD-L1 expression. The survival benefit increased with the level of PD-L1 expression: tumor PD-L1 1% (16.7 versus 12.1 months); 20% (17.7 versus 13 months); 50% (20 versus 12.2 months). Lower rates of severe side effects were observed in the pembrolizumab arm versus the chemotherapy arm (18% versus 41%). Further studies are warranted to better stratify patients who would benefit from pembrolizumab, and investigate head-to-head comparison of pembrolizumab alone and in combination with chemotherapy in patients with PD-L1 expression. Preliminary data from the substudy of Circulating Cell-Free Genome Atlas (CCGA), spanning 141 sites in the US and Canada, demonstrated that plasma cell-free DNA could detect early-stage lung cancer with low rate of false-positive results. Three different prototype sequencing assays using plasma cell-free DNA were evaluated for its ability to detect cancer in 127 patients with stage I to IV lung cancer. Wholegenome bisulfite sequencing (WGBS), with 98% specificity, detected 41% of early-stage and 89% of late-stage lung cancers. Whole-genome sequencing (WGS) detected 38% of early-stage and 87% of late-stage lung cancers. Targeted sequencing detected 51% of early-stage and 89% of late-stage lung cancers. Another important finding was more than 54% somatic mutations detected were not from tumors but white blood cells as a result of natural aging, which should be taken into consideration in the development of blood tests for early cancer detection. Preliminary findings from the randomized phase III study demonstrated that patients with stage IV squamous NSCLC, regardless of PD-L1 expression, receiving the anti-PD-L1 atezolizumab in combination with chemotherapy (carboplatin and nab-paclitaxel) benefit more than those treated with chemotherapy alone. The combination arm achieved a median progression-free survival (PFS) of 6.3 months versus 5.6 months in the chemotherapy alone arm (hazard ratio, HR¼0.715; P ¼ 0.0001). PFS at 12 months was doubled in the combination arm versus the chemotherapy alone arm (24.7% versus 12.0%). The combination arm had a higher rate of severe side-effects (68% versus 57%) but with a manageable safety profile that is consistent with known safety risks of the individual treatment components. The most common side effects of atezolizumab included skin rash, colitis, and low thyroid hormone levels. . Improved progression-free survival (PFS) was also observed in the pembrolizumab combination versus chemotherapy alone (HR ¼ 0.56; P <0.0001). Similarly, the observation was independent of PD-L1 expression (HR ¼ 0.68, 0.56 and 0.37, respectively). The overall response rate was 57.9% with pembrolizumab combination and 38.4% with chemotherapy alone, with median duration of response of 7.7 months and 4.8 months, respectively. Updated findings of the phase III ALEX trial demonstrated a median progression-free survival (PFS) of 34.8 months with alectinib (n¼152) versus 10.9 months with crizotinib (n¼151) in the first-line setting for patients with ALKpositive NSCLC. The PFS was nearly identical in patients with no brain metastases at diagnosis. Brain metastases developed in 12% of the alectinib arm versus 45% of the crizotinib arm. Overall response rate was 82.9% with alectinib versus 75.5% with crizotinib. Less overall side effects were observed with alectinib versus crizotinib (dose reduction: 16% versus 21%; dose interruption: 21% versus 25%).
News from the IASLC Tobacco Control Committee
If You Ever Wondered Why.
Sometimes the complexity and sheer vigilance required for effective tobacco control seems extraordinary. Why can't we control tobacco, more than 50 years after the initial US Surgeon General's report on its disastrous health effects? 1 Why weren't those data enough? And what about all of the data since, on lung cancer, on cardiovascular disease, on second-hand smoke exposure? The resistance of the tobacco epidemic to advocacy, activism, policy and science is, at times, astounding.
In 1986, 22 years after the Surgeon General's report and 32 years ago, an episode of Yes, Prime Minister was broadcast, looking at the very issue. This was a popular British comedy series that lampooned the political and bureaucratic culture of the day in ways that remain startlingly relevant. In the transcript below (about 10m05s into the recording HA: (sanctimonious concern).Yes of course, Prime Minister. Please, don't misunderstand me. It is quite right of course that you should contemplate all proposals that come from your government, but no sane man would ever support it.
PM: (a serious look) I'm supporting it.
HA: (frowning) And quite right too, Prime Minister, if I may say. You see,the only little problem is that the tax on tobacco is a major source of revenue for the government.
PM: It is also a major source of death from killer diseases.
HA: (solicitously) Yes indeed, but no definite causative link has ever been proved, has it? promotion of tobacco information services including a free phone line, website, phone app and Facebook page. Television promotion spots were reserved for smokers who quit successfully using one of these resources. France sits at the top of the 3rd quartile for smoking prevalence world-wide -a fun interactive graph from the WHO 2 puts it just above Malta and just below Jamaica for 2015 data, well above the lowest end of the spectrum (Ethopia 8.9%) and well below the top (Indonesia, 76.2%). Other contributing factors, according to a CNN report 3 , may include increases in tobacco taxation and subsequent price rises. France had an excise tax on tobacco of 63.3% in 2015 3 , below the WHO recommended minimum level of 70%. 3 It is hard (impossible?) to find a fun interactive map of global tobacco excise tax levels, but the World Economic Forum lists countries with the highest excise tax rates 4 with Eastern Europe dominating the draw. Rises in tobacco excise tax, based on the quantity of tobacco, generally have more impact on tobacco consumption than other less structured taxation, where price rises can be avoided by switching to cheaper brands. A recent analysis of survey data from the International Tobacco Control (ITC) Policy Evaluation Project confirms the benefit of uniform and specific (eg excise) over tiered and ad valorem (based on tobacco value taxation). 
